Publications by authors named "Sarah Hollick"
The immune-modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic in breast cancer.
View Article and Find Full Text PDFArticle Synopsis
- Many patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) do not respond well to immune checkpoint blockade (ICB) treatments and often suffer from adverse side effects, highlighting the need for predictive biomarkers like DNA methylation of the CTLA4 gene.
- The study analyzed CTLA4 promoter methylation in tumors of HNSCC patients who received ICB treatment, revealing that lower methylation levels were associated with better treatment responses and longer progression-free survival.
- The findings suggest that hypomethylation of the CTLA4 gene may serve as a useful predictive biomarker for ICB effectiveness in HNSCC, and further research is encouraged in clinical trials involving immunotherapies.*